Vertaling van "review and meta-analysis of randomised " (Frans → Nederlands) :

10. Chang A, Lasserson T, Kiljander T et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions
Chang A, Lasserson T, Kiljander T et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions

Table 3: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.
Table 1: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.

Table 9: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 7: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence

DOI : 10.1002/ 14651858.CD008143.pub2. Boussageon R, Bejan-Angoulvant T, Saadatian M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R, Bejan-Angoulvant T, Saadatian M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. A meta-analysis.

Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.
DOI: 10.1002/14651858.CD000254.pub3. Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

forms of vitamin D: a meta-analysis of randomised controlled trials.
active forms of vitamin D: a meta-analysis of randomised controlled trials.

Bischoff-Ferrari HA, Dawson-Hughes B, Stahelin HB et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised
However, harmful effects associated with long-term vitamin supplementation, particularly in smokers and people with vascular disease, cannot be ruled out.

Winblad B, Jones RW, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials.
Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials.

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)